Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells

Proteomics

Volumn 11, Issue 18, 2011, Pages 3725-3742

  Bianchi, Laura ^a   Bruzzese, Francesca ^b   Leone, Alessandra ^b   Gagliardi, Assunta ^a   Puglia, Michele ^a   Di Gennaro, Elena ^b   Rocco, Monia ^b   Gimigliano, Anna ^a   Pucci, Biagio ^b   Armini, Alessandro ^a   Bini, Luca ^a   Budillon, Alfredo ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

2 D DIGE; Cell biology; Gefitinib; Histone deacetylase; MS; Vorinostat

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HEP 2 CELL; HUMAN; HUMAN CELL; ION TRAP MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; SOLID TUMOR; TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION PROCESS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; MASS SPECTROMETRY; PEPTIDE MAPPING; PROTEIN ISOFORMS; PROTEOMICS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SOFTWARE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 80052516132     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100092     Document Type: Article

References (76)

1. Budillon, A., Di Gennaro, E., Bruzzese, F., Rocco, M. et al., Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. Recent Pat. Anticancer Drug Discov. 2007, 2, 119-134.
2. Buchwald, M., Kramer, O. H., Heinzel, T., HDACi - targets beyond chromatin. Cancer Lett. 2009, 280, 160-167.
3. Budillon, A., Bruzzese, F., Di Gennaro, E., Caraglia, M., Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. Curr. Drug Targets 2005, 6, 337-351.
4. Lane, A. A., Chabner, B. A., Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27, 5459-5468.
5. Marks, P. A., Discovery and development of SAHA as an anticancer agent. Oncogene 2007, 26, 1351-1356.
6. Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H. et al., Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 3923-3931.
7. Richon, V. M., Garcia-Vargas, J., Hardwick, J. S., Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009, 280, 201-210.
8. O'Connor, O. A., Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma. Br. J. Cancer 2006, 95, S7-S12.
9. Di Gennaro, E., Barbarino, M., Bruzzese, F., De Lorenzo, S. et al., Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J. Cell Physiol. 2003, 195, 139-150.
10. Bruzzese, F., Leone, A., Rocco, M., Carbone, C. et al., HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J. Cell Physiol. 2011, 226, 2378-2390.
11. Hickinson, D. M., Marshall, G. B., Beran, G. J., Varella-Garcia, M. et al., Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. Clin. Transl. Sci. 2009, 2, 183-192.
12. Larbi, N. B., Jefferies, C., 2D-DIGE: comparative proteomics of cellular signalling pathways. Methods Mol. Biol. 2009, 517, 105-132.
13. Weiss, W., Gorg, A., High-resolution two-dimensional electrophoresis. Methods Mol. Biol. 2009, 564, 13-32.
14. Bjellqvist, B., Hughes, G. J., Pasquali, C., Paquet, N. et al., The focusing positions of polypeptides in immobilized pH gradients can be predicted from their amino acid sequences. Electrophoresis 1993, 14, 1023-1031.
15. Bianchi, L., Lorenzoni, P., Bini, L., Weber, E. et al., Protein expression profiles of Bos taurus blood and lymphatic vessel endothelial cells. Proteomics 2007, 7, 1600-1614.
16. Sinha, P., Poland, J., Schnolzer, M., Rabilloud, T., A new silver staining apparatus and procedure for matrix-assisted laser desorption/ionization-time of flight analysis of proteins after two-dimensional electrophoresis. Proteomics 2001, 1, 835-840.
17. Hellman, U., Wernstedt, C., Gonez, J., Heldin, C. H., Improvement of an "In-Gel" digestion procedure for the micropreparation of internal protein fragments for amino acid sequencing. Anal. Biochem. 1995, 224, 451-455.
18. Soskic, V., Gorlach, M., Poznanovic, S., Boehmer, F. D., Godovac-Zimmermann, J., Functional proteomics analysis of signal transduction pathways of the platelet-derived growth factor beta receptor. Biochemistry 1999, 38, 1757-1764.
19. Di Gennaro, E., Bruzzese, F., Pepe, S., Leone, A. et al., Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol. Ther. 2009, 8, 782-791.
20. Bruzzese, F., Rocco, M., Castelli, S., Di Gennaro, E. et al., Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol. Cancer Ther. 2009, 8, 3075-3087.
21. Witta, S. E., Gemmill, R. M., Hirsch, F. R., Coldren, C. D. et al., Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006, 66, 944-950.
22. Edwards, A., Li, J., Atadja, P., Bhalla, K., Haura, E. B., Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol. Cancer Ther. 2007, 6, 2515-2524.
23. Chinnaiyan, P., Varambally, S., Tomlins, S. A., Ray, S. et al., Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. Int. J. Cancer 2006, 118, 1041-1050.
24. Wan, G., Zhou, L., Xie, M., Chen, H., Tian, J., Characterization of side population cells from laryngeal cancer cell lines. Head Neck 2010, 32, 1302-1309.
25. Skvortsova, I., Skvortsov, S., Raju, U., Stasyk, T. et al., Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse. Radiother Oncol. 2010, 96, 108-115.
26. Smith, A. P., Verrecchia, A., Faga, G., Doni, M. et al., A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene 2009, 28, 422-430.
27. Liu, M., Casimiro, M. C., Wang, C., Shirley, L. A. et al., p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc. Natl. Acad. Sci. USA 2009, 106, 19035-19039.
28. Wang, L. G., Liu, X. M., Fang, Y., Dai, W. et al., De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int. J. Oncol. 2008, 33, 375-380.
29. Fritz, V., Fajas, L., Metabolism and proliferation share common regulatory pathways in cancer cells. Oncogene 2010, 29, 4369-4377.
30. Luo, J., Solimini, N. L., Elledge, S. J., Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136, 823-837.
31. Du, Z. X., Wang, H. Q., Zhang, H. Y., Gao, D. X., Involvement of glyceraldehyde-3-phosphate dehydrogenase in tumor necrosis factor-related apoptosis-inducing ligand-mediated death of thyroid cancer cells. Endocrinology 2007, 148, 4352-4361.
32. Chang, Y. S., Wu, W., Walsh, G., Hong, W. K., Mao, L., Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin. Cancer Res. 2003, 9, 3641-3644.
33. Cappello, P., Tomaino, B., Chiarle, R., Ceruti, P. et al., An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int. J. Cancer 2009, 125, 639-648.
34. Tu, S. H., Chang, C. C., Chen, C. S., Tam, K. W. et al., Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res. Treat. 2010, 121, 539-553.
35. Ghosh, A. K., Steele, R., Ray, R. B., MBP-1 physically associates with histone deacetylase for transcriptional repression. Biochem. Biophys. Res. Commun. 1999, 260, 405-409.
36. Trojanowicz, B., Winkler, A., Hammje, K., Chen, Z. et al., Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines. J. Mol. Endocrinol. 2009, 42, 249-260.
37. Gavert, N., Ben-Ze'ev, A., Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol. Med. 2008, 14, 199-209.
38. Frederick, B. A., Helfrich, B. A., Coldren, C. D., Zheng, D. et al., Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol. Cancer Ther. 2007, 6, 1683-1691.
39. Haddad, Y., Choi, W., McConkey, D. J., Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin. Cancer Res. 2009, 15, 532-542.
40. Erjala, K., Sundvall, M., Junttila, T. T., Zhang, N. et al., Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin. Cancer Res. 2006, 12, 4103-4111.
41. Chen, L. F., Cohen, E. E., Grandis, J. R., New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin. Cancer Res. 2010, 16, 2489-2495.
42. Wheeler, D. L., Dunn, E. F., Harari, P. M., Understanding resistance to EGFR inhibitors - impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010, 7, 493-507.
43. Lahat, G., Zhu, Q. S., Huang, K. L., Wang, S. et al., Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 2010, 5, e10105.
44. Milli, A., Cecconi, D., Campostrini, N., Timperio, A. M. et al., A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells. Biochim. Biophys. Acta 2008, 1784, 1702-1710.
45. Zhang, Y., Woodford, N., Xia, X., Hamburger, A. W., Repression of E2F1-mediated transcription by the ErbB3 binding protein Ebp1 involves histone deacetylases. Nucleic Acids Res. 2003, 31, 2168-2177.
46. Zhang, Y., Akinmade, D., Hamburger, A. W., Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1. Cancer Lett. 2008, 265, 298-306.
47. Zhang, Y., Linn, D., Liu, Z., Melamed, J. et al., EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol. Cancer Ther. 2008, 7, 3176-3186.
48. Liu, Z., Ahn, J. Y., Liu, X., Ye, K., Ebp1 isoforms distinctively regulate cell survival and differentiation. Proc. Natl. Acad. Sci. USA 2006, 103, 10917-10922.
49. Liu, Z., Oh, S. M., Okada, M., Liu, X. et al., Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor. Mol. Biol. Cell 2009, 20, 757-768.
50. Kim, C. K., Nguyen, T. L., Joo, K. M., Nam, D. H. et al., Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. Cancer Res. 2010, 70, 9730-9741.
51. Bommer, U. A., Thiele, B. J., The translationally controlled tumour protein (TCTP). Int. J. Biochem. Cell Biol. 2004, 36, 379-385.
52. Bazile, F., Pascal, A., Arnal, I., Le Clainche, C. et al., Complex relationship between TCTP, microtubules and actin microfilaments regulates cell shape in normal and cancer cells. Carcinogenesis 2009, 30, 555-565.
53. Susini, L., Besse, S., Duflaut, D., Lespagnol, A. et al., TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ. 2008, 15, 1211-1220.
54. Koziol, M. J., Garrett, N., Gurdon, J. B., Tpt1 activates transcription of oct4 and nanog in transplanted somatic nuclei. Curr. Biol. 2007, 17, 801-807.
55. Cecconi, D., Scarpa, A., Donadelli, M., Palmieri, M. et al., Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A. Electrophoresis 2003, 24, 1871-1878.
56. Thinnes, F. P., Neuroendocrine differentiation of LNCaP cells suggests: VDAC in the cell membrane is involved in the extrinsic apoptotic pathway. Mol. Genet. Metab. 2009, 97, 241-243.
57. Tajeddine, N., Galluzzi, L., Kepp, O., Hangen, E. et al., Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008, 27, 4221-4232.
58. Chacko, A. D., Liberante, F., Paul, I., Longley, D. B., Fennell, D. A., Voltage dependent anion channel-1 regulates death receptor mediated apoptosis by enabling cleavage of caspase-8. BMC Cancer 2010, 10, 380.
59. Reddy, R. K., Mao, C., Baumeister, P., Austin, R. C. et al., Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J. Biol. Chem. 2003, 278, 20915-20924.
60. Shi, Y., Gerritsma, D., Bowes, A. J., Capretta, A., Werstuck, G. H., Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition. Bioorg. Med. Chem. Lett. 2007, 17, 4491-4494.
61. Baumeister, P., Dong, D., Fu, Y., Lee, A. S., Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis. Mol. Cancer Ther. 2009, 8, 1086-1094.
62. Kahali, S., Sarcar, B., Fang, B., Williams, E. S. et al., Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Neoplasia 2010, 12, 80-86.
63. Rao, R., Nalluri, S., Kolhe, R., Yang, Y. et al., Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. Mol. Cancer Ther. 2010, 9, 942-952.
64. Ungerstedt, J. S., Sowa, Y., Xu, W. S., Shao, Y. et al., Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 2005, 102, 673-678.
65. Ruefli, A. A., Ausserlechner, M. J., Bernhard, D., Sutton, V. R. et al., The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 2001, 98, 10833-10838.
66. Rosato, R. R., Kolla, S. S., Hock, S. K., Almenara, J. A. et al., Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J. Biol. Chem. 2010, 285, 10064-10077.
67. Sanda, T., Okamoto, T., Uchida, Y., Nakagawa, H. et al., Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia 2007, 21, 2344-2353.
68. Zhang, Y., Gu, J., Zhao, L., He, L. et al., Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer Res. 2006, 66, 4291-4298.
69. Laurent, A., Nicco, C., Chereau, C., Goulvestre, C. et al., Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005, 65, 948-956.
70. Hu, Y., Rosen, D. G., Zhou, Y., Feng, L. et al., Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J. Biol. Chem. 2005, 280, 39485-39492.
71. Karihtala, P., Mantyniemi, A., Kang, S. W., Kinnula, V. L., Soini, Y., Peroxiredoxins in breast carcinoma. Clin. Cancer Res. 2003, 9, 3418-3424.
72. Parmigiani, R. B., Xu, W. S., Venta-Perez, G., Erdjument-Bromage, H. et al., HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc. Natl. Acad. Sci. USA 2008, 105, 9633-9638.
73. Zhang, Y., Emmanuel, N., Kamboj, G., Chen, J. et al., PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22). Genes Chromosomes Cancer 2004, 40, 365-370.
74. Rauch, J., O'Neill, E., Mack, B., Matthias, C. et al., Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription. Cancer Res. 2010, 70, 1679-1688.
75. Zhou, Q., Chaerkady, R., Shaw, P. G., Kensler, T. W. et al., Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics 2010, 10, 1029-1039.
76. Park, E. S., Rabinovsky, R., Carey, M., Hennessy, B. T. et al., Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol. Cancer Ther. 2010, 9, 257-267.